Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
naloxone
Pharma
Orexo's opioid overdose nasal spray is rejected again by FDA
For the second time in 15 months, the FDA has rejected Orexo’s OX124 (naloxone), a high-dose nasal spray rescue treatment for opioid overdoses.
Kevin Dunleavy
Jul 17, 2024 10:47am
'The Top Line': A series on Narcan, plus this week's headlines
Apr 28, 2023 6:00am
Emergent's Narcan wins over-the-counter nod from FDA
Mar 29, 2023 11:28am
Catalent chips in on Harm Reduction's OTC naloxone push
Mar 23, 2023 2:43pm
FDA expert panel unanimously backs over-the-counter Narcan nod
Feb 16, 2023 2:46pm
Orexo seeks approval of nasal high-dose opioid rescue medicine
Feb 7, 2023 8:40am
